Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABACUS trial of abiraterone acetate for Cushing's syndrome in adrenocortical carcinoma
2016-000945-29Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in Cushing's syndrome and adrenal cancer (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Normalization of 24-hour urinary free cortisol. Started Nov 2020; status: completed.
02
Drugs
abiraterone
03
Conditions
Cushing's syndromeadrenal cancer (ACC)
Beyond the preview
Go deeper on 2016-000945-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000945-29.